CUE News and Press, Cue Biopharma Inc. From 05/10/21

Cue Biopharma (CUE) gains 8% premarket after announcing interim clinical data from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSC...

And Provides Interim Clinical Data Update Partial response data demonstrates activity of CUE-101 as monotherapy in patient with human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC) The objective tumor response observe...

CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, anno...

The following slide deck was published by Cue Biopharma, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Cue Biopharma, Inc. 2021 Q4 - Results - Earnings Call Presentation

Cue Biopharma, Inc. (CUE) Q4 2020 Earnings Conference Call March 16, 2021, 16:30 ET Company Participants George Zavoico - VP, IR & Corporate Development Daniel Passeri - CEO & Director Kenneth Pienta - Acting Chief Medical Officer Matteo Levisetti - SVP, Clinical Development Anish Sur...

Cue Biopharma (CUE): Q4 GAAP EPS of -$0.37 beats by $0.03.Revenue of $0.46M (-56.2% Y/Y) misses by $0.61M.Press Release For further details see: Cue Biopharma EPS beats by $0.03, misses on revenue

Evaluated initial observations in CUE-101 Phase 1 monotherapy dose escalation clinical trial for treatment of human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC), which demonstrated tolerability and generated encouraging emerging me...

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, an...

Anchiano Therapeutics (ANCN) +66%.Second Sight Medical Products (EYES) +38%.OpGen (OPGN) +29% after publication of final study results of Unyvero HPN Panel.Net Element (NETE) +19% on strategic partnership with Mullen technologies.Athene Holding Ltd. (ATH) +18%&#x...

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced t...